

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

9

Complete if Known

Application No. 09/899,422
 Filing Date: 7-3-01
 First Named Inventor Hauptmann et al.
 Group Art Unit 1646
 Examiner Name Eilon O'Hara
 Attorney Docket No. 98,385-H

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code ² (if known)			
EA	26	5,633,145		Feldmann et al.	May 27, 1997	
	27	5,695,953		Wallach et al.	Dec. 9, 1997	
	28	5,712,155		Smith et al.	Jan. 27, 1998	
	29	5,808,029		Brockhaus et al.	Sep. 15, 1998	
	30	5,811,261		Wallach et al.	Sep. 22, 1998	
	31	5,843,791		Hauptmann et al.	Dec. 1, 1998	
✓	32	5,863,786		Feldmann et al.	Jan. 26, 1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T ⁶
		Number ⁴	Kind Code ⁵ (if known)				
EA	33	DE03910323A1		10/1989			
	34	DE03913101.7					
EA	35	DE0920282.8		08/1992			
	36	EP0154316A2		09/1985			
	37	EP0154316B1		09/1989			
	38	EP0162699		11/1985			
	39	EP0225579A3		11/1989			
	40	EP0247860A2		12/1987			
	41	EP0259863A2		03/1988			
	42	EP0308378		03/1989			
	43	EP0334165A2		09/1989			
✓	44	EP0393438A2		10/1990			

Eilon O'Hara

8/26/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

MR
2-24-7



Complete If Known

Application No.	09/899,422
Filing Date:	7-3-01
First Named Inventor	Hauptmann et al.
Group Art Unit	1646
Examiner Name	Eileen O'Hara
Attorney Docket No.	98,385-H

Sheet

of

9

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T ^o
		Number ⁴	Kind Code ⁵ (if known)				
EA	45	EP0398327A1			11/1990		
	46	EP0412486			02/1991		
	47	EP0417563A2			03/1991		
	48	EP0418014A1			03/1991		
	49	EP0422339			04/1991		
	50	EP0433900			06/1991		
	51	EP0512528A2			11/1992		
	52	EP0526905A2			02/1993		
	53	GB2218101			11/1989		
	54	GB2246569A			02/1992		
	55	WO90/13575			11/1990		
	56	WO91/03553			03/1991		
	57	WO92/01002			01/1992		
	58	WO92/07076			04/1992		
	59	WO92/13095			08/1992		
	60	WO92/15682			09/1992		
	61	WO92/16221			10/1992		
	62	WO92/01474			02/1992		
	63	WO94/08476			03/1994		

MR
2-23-07

Eileen O'Hara 8/26/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

SUBSTITUTE FOR FORM Y-29, PTO MAR 19 2004 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete If Known	
				Application No.	09/899,422
				Filing Date:	7-3-01
				First Named Inventor	Hauptmann
				Group Art Unit	1646
				Examiner Name	E. O'Hara
Sheet 1 of 1	Attorney Docket No.	98-385-H			

U.S. PATENT DOCUMENTS						
Examiner Initials ^a	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials ^a	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
EPA		DE	3913101.7	A1	Boehringer Ingelheim International GmbH	04-1989		

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials ^a	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T ²
EPA		HELLER <i>et al.</i> , "Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor," <i>Proc. Natl. Acad. Sci.</i> 87: 6151-55 (1990).		
		PEPPEL <i>et al.</i> , "A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity," <i>J. Exp. Med.</i> 174:1483-89 (1991).		
		TSUJIMOTO <i>et al.</i> , "Characterization and Affinity Crosslinking of Receptors for Tumor Necrosis Factor on Human Cells," <i>Archives of Biochemistry</i> 249(2):563-568(1986).		
		POWELL <i>et al.</i> , "The Role of Lymphotoxin and TNF in Demyelinating Diseases of the CNS," <i>Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine.</i> pgs 355-69.		
		RHEIN <i>et al.</i> , "Another Sepsis Drug Down-Immunex TNF Receptor," <i>Biotechnology Newswatch</i> , pg. 1,3 (Monday, October 4, 1991).		
		VILCEK <i>et al.</i> , "Tumor Necrosis Factor: Receptor Binding and Mitogenic Action in Fibroblasts," <i>J. Cell. Physiol.</i> 5:57-61 (1987).		
✓		SMITH <i>et al.</i> , "Species Specificity of Human and Murine Tumor Necrosis Factor," <i>The Journal of Biological Chemistry</i> , 251(32):14871-148874 (1986).		

Examiner Signature	<i>Eileen B. O'Hara</i>	Date Considered	5/21/04
--------------------	-------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

BEST AVAILABLE COPY